Why did Biogen cut its 2026 adjusted per-share profit forecast, and by how much?

Biogen cut its 2026 adjusted per-share profit forecast to between $12 and $13 from $14.25–$15.25 earlier, reflecting a $3.85 per share impact from acquisition-related charges, including an 85-cent-per-share hit from its $5.6 billion buyout of Apellis Pharmaceuticals.

What drove Biogen's second-quarter earnings beat, and how did sales of its newer versus legacy drugs perform?

Biogen's second-quarter earnings beat was driven by strong demand for its rare-disease medicines and growth in global sales of its Alzheimer's drug Leqembi—which rose 15% year-over-year to $184 million—while sales of legacy multiple sclerosis drugs like Tecfidera fell 13% to $963 million year-over-year.

Biogen Beats Quarterly Estimates as Newer Drugs Fuel Growth

Jul 29, 2026

Biogen reported Q2 profits exceeding estimates driven by rare-disease medicines and Leqembi sales, though legacy MS drug revenue declined. The company cut its 2026 profit forecast following an $5.6 billion acquisition of Apellis Pharmaceuticals.

reuters

2026-05-26

Italy's antitrust regulator opens probe into US Biogen over alleged dominant position

2026-07-29

Biogen Beats Quarterly Estimates as Newer Drugs Fuel Growth

Biogen Beats Quarterly Estimates as Newer Drugs Fuel Growth

FAQ